Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Renal Cell Carcinoma

December 21, 2018

Management of Renal Cell Carcinoma (RCC)
For patients with early stage RCC, several factors are taken into consideration to help determine which surgical approach should be adopted.  Careful selection of patients for appropriate surgery, depending upon the extent of disease is very critical. Also, with the approval of adjuvant sunitinib, the treatment paradigm for early stage disease is changing. It is important for clinicians’ to understand the patients who would benefit from adjuvant systemic therapy.  

Patients with advanced RCC will be exposed to multiple agents during their continuum of care. Clinicians need to stay current with their knowledge of the benefits and risks of the multiple acceptable treatment strategies and apply high-level clinical evidence and expert advice to individualize treatment and maximize outcomes for these patients.

Target Audience

This educational program is designed to meet the educational needs of physicians, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Identify key patient and clinical factors that influence choice of adjuvant therapy for early stage renal cell carcinoma (RCC).
  • Evaluate the benefits and risks associated with therapies and use evidence-based data and patient characteristics to select optimal first line treatment for patients with advanced RCC.
  • Design optimal treatment plans after disease progression in patients with advanced RCC.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Astellas
  • AstraZeneca
  • Bayer U.S. LLC
  • Celgene Corporation
  • Clovis Oncology
  • Eisai
  • Genentech
  • Jazz Pharmaceuticals, Inc.
  • Lilly
  • Novartis
  • Taiho Oncology

This activity is supported by an independent educational grant from TESARO.

This activity is supported by an independent medical education grant from Bristol-Myers Squibb.

This educational activity is supported by a medical education grant from Exelixis, Inc.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
10/29/2018
Course expires: 
02/17/2019
Event starts: 
12/21/2018 - 1:30pm
Event ends: 
12/21/2018 - 2:30pm
Cost:
$0.00
Parent activity set: 

Elizabeth R. Plimack, MD, MS
Fox Chase Cancer Center

Robert G. Uzzo, MD
Fox Chase Cancer Center

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below disclose the following relevant financial relationships:
Elizabeth R. Plimack, MD, MS
AstraZeneca Pharmaceuticals LP: Grant/Research Support; Scientific Advisor
Bristol-Myers Squibb Company: Grant/Research Support; Scientific Advisor
Genentech, Inc.: Grant/Research Support; Scientific Advisor
Incyte Corporation: Scientific Advisor
Inovio: Scientific Advisor
Janssen Pharmaceutica Products, LP: Scientific Advisor
Merck & Co., Inc.: Grant/Research Support; Scientific Advisor
Peloton Therapeutics, Inc.: Grant/Research Support
Pfizer Inc.: Grant/Research Support; Scientific Advisor

Robert G. Uzzo, MD
Genentech, Inc.: Scientific Advisor
Janssen Pharmaceutica Products, LP: Honoraria; Scientific Advisor
Novartis Pharmaceuticals Corporation: Grant/Research Support
Pfizer Inc.: Honoraria

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS (employed by NCCN until 8/1/2018); Lisa Perfidio, MS; Shannon Ryan; Kathy Ann Smith, CMP, CHCP

The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Donald Harting, ELS, CHCP (employed by NCCN until 12/3/2018)
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options

Katherine Pierce (employed by NCCN until 11/16/2018)
Boston Scientific Corporation: Equity Interest/Stock Options
Pfizer Inc.: Equity Interest/Stock Options

The NCCN Clinical staff listed below discloses the following relevant financial relationships: 
Griselda Zuccarino-Catania, PhD
Janssen Pharmaceutica Products, LP: Salary (Spouse)

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category 1 credit for completing this activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00034811; Approval #: 180004496

Pharmacists

National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-18-143-L01-P

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Accreditation Period

Course opens: 
10/29/2018
Course expires: 
02/17/2019

Price

Cost:
$0.00
Please login or register to take this course.

This webinar was presented live one time only on Friday, December 21, 2018, from 1:30 - 2:30 PM Eastern Standard Time (EST) (UTC -5).

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing